FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046290421> ?p ?o ?g. }

• W2046290421 endingPage "740" @default.
• W2046290421 startingPage "733" @default.
• W2046290421 abstract "Purpose To investigate the association between visual field defects and quality of life in the United States population. Design Cross-sectional study. Participants A total of 5186 participants in the 2005 through 2008 National Health and Nutrition Examination Survey 40 years of age and older without a self-reported history of age-related macular degeneration or prior refractive surgery who had undergone frequency doubling technology perimetric testing. Methods Frequency doubling technology perimetry was performed in both eyes. Results from the better eye were used to categorize subjects as normal or having mild, moderate, or severe visual field loss. Subjects completed surveys about their visual and physical functioning ability. Main Outcome Measures Disability pertaining to 6 vision-related activities, 2 visual function questions, and 5 physical functioning domains. Results Eighty-one percent of subjects had normal visual fields and 10%, 7%, and 2% demonstrated mild, moderate, and severe visual field defects, respectively. Subjects with greater severity of visual field defects had greater difficulty with vision-related activities. Subjects with severe visual field defects demonstrated the greatest odds of difficulty with all 6 activities. The 2 activities impacted most adversely were daytime driving in familiar places (odds ratio [OR], 12.4; 95% confidence interval [CI], 6.1–25.1) and noticing objects off to the side when walking (OR, 7.7; 95% CI, 4.7–12.7). Subjects with severe visual field defects had greater odds of worrying about eyesight (OR, 3.4; 95% CI, 2.0–5.8) and being limited by vision in the time spent on daily activities (OR, 5.1; 95% CI, 3.0–8.5). Subjects with severe visual field defects demonstrated the greatest odds of difficulty with 3 physical function domains, including activities of daily living (OR, 2.45; 95% CI, 1.37–4.38), instrumental activities of daily living (OR, 2.45; 95% CI, 1.37–4.38), as well as leisure and social activities (OR, 3.29; 95% CI, 1.87–5.77). Conclusions Greater severity of visual field abnormality was associated with significantly greater odds of disability with vision-related function and physical function. These findings support the necessity of routine screening to find those who may benefit from therapy to prevent progressive glaucomatous vision loss. To investigate the association between visual field defects and quality of life in the United States population. Cross-sectional study. A total of 5186 participants in the 2005 through 2008 National Health and Nutrition Examination Survey 40 years of age and older without a self-reported history of age-related macular degeneration or prior refractive surgery who had undergone frequency doubling technology perimetric testing. Frequency doubling technology perimetry was performed in both eyes. Results from the better eye were used to categorize subjects as normal or having mild, moderate, or severe visual field loss. Subjects completed surveys about their visual and physical functioning ability. Disability pertaining to 6 vision-related activities, 2 visual function questions, and 5 physical functioning domains. Eighty-one percent of subjects had normal visual fields and 10%, 7%, and 2% demonstrated mild, moderate, and severe visual field defects, respectively. Subjects with greater severity of visual field defects had greater difficulty with vision-related activities. Subjects with severe visual field defects demonstrated the greatest odds of difficulty with all 6 activities. The 2 activities impacted most adversely were daytime driving in familiar places (odds ratio [OR], 12.4; 95% confidence interval [CI], 6.1–25.1) and noticing objects off to the side when walking (OR, 7.7; 95% CI, 4.7–12.7). Subjects with severe visual field defects had greater odds of worrying about eyesight (OR, 3.4; 95% CI, 2.0–5.8) and being limited by vision in the time spent on daily activities (OR, 5.1; 95% CI, 3.0–8.5). Subjects with severe visual field defects demonstrated the greatest odds of difficulty with 3 physical function domains, including activities of daily living (OR, 2.45; 95% CI, 1.37–4.38), instrumental activities of daily living (OR, 2.45; 95% CI, 1.37–4.38), as well as leisure and social activities (OR, 3.29; 95% CI, 1.87–5.77). Greater severity of visual field abnormality was associated with significantly greater odds of disability with vision-related function and physical function. These findings support the necessity of routine screening to find those who may benefit from therapy to prevent progressive glaucomatous vision loss." @default.
• W2046290421 created "2016-06-24" @default.
• W2046290421 creator A5000683013 @default.
• W2046290421 creator A5001768900 @default.
• W2046290421 creator A5021443603 @default.
• W2046290421 creator A5027121559 @default.
• W2046290421 date "2014-03-01" @default.
• W2046290421 modified "2023-10-03" @default.
• W2046290421 title "Association between Visual Field Defects and Quality of Life in the United States" @default.
• W2046290421 cites W1964001129 @default.
• W2046290421 cites W1979846948 @default.
• W2046290421 cites W1987082230 @default.
• W2046290421 cites W1987621316 @default.
• W2046290421 cites W2018021100 @default.
• W2046290421 cites W2022871200 @default.
• W2046290421 cites W2024475596 @default.
• W2046290421 cites W2044256269 @default.
• W2046290421 cites W2046676328 @default.
• W2046290421 cites W2057266151 @default.
• W2046290421 cites W2065334523 @default.
• W2046290421 cites W2079481914 @default.
• W2046290421 cites W2086592233 @default.
• W2046290421 cites W2087127132 @default.
• W2046290421 cites W2092319520 @default.
• W2046290421 cites W2096060458 @default.
• W2046290421 cites W2105989442 @default.
• W2046290421 cites W2116411676 @default.
• W2046290421 cites W2140594570 @default.
• W2046290421 cites W2148890166 @default.
• W2046290421 cites W2172151487 @default.
• W2046290421 cites W4293101293 @default.
• W2046290421 doi "https://doi.org/10.1016/j.ophtha.2013.09.043" @default.
• W2046290421 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3943627" @default.
• W2046290421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24342021" @default.
• W2046290421 hasPublicationYear "2014" @default.
• W2046290421 type Work @default.
• W2046290421 sameAs 2046290421 @default.
• W2046290421 citedByCount "45" @default.
• W2046290421 countsByYear W20462904212014 @default.
• W2046290421 countsByYear W20462904212015 @default.
• W2046290421 countsByYear W20462904212016 @default.
• W2046290421 countsByYear W20462904212017 @default.
• W2046290421 countsByYear W20462904212018 @default.
• W2046290421 countsByYear W20462904212019 @default.
• W2046290421 countsByYear W20462904212021 @default.
• W2046290421 countsByYear W20462904212022 @default.
• W2046290421 countsByYear W20462904212023 @default.
• W2046290421 crossrefType "journal-article" @default.
• W2046290421 hasAuthorship W2046290421A5000683013 @default.
• W2046290421 hasAuthorship W2046290421A5001768900 @default.
• W2046290421 hasAuthorship W2046290421A5021443603 @default.
• W2046290421 hasAuthorship W2046290421A5027121559 @default.
• W2046290421 hasBestOaLocation W20462904212 @default.
• W2046290421 hasConcept C118487528 @default.
• W2046290421 hasConcept C118552586 @default.
• W2046290421 hasConcept C119767625 @default.
• W2046290421 hasConcept C126322002 @default.
• W2046290421 hasConcept C142052008 @default.
• W2046290421 hasConcept C142724271 @default.
• W2046290421 hasConcept C143095724 @default.
• W2046290421 hasConcept C151956035 @default.
• W2046290421 hasConcept C154945302 @default.
• W2046290421 hasConcept C156957248 @default.
• W2046290421 hasConcept C159110408 @default.
• W2046290421 hasConcept C2776058522 @default.
• W2046290421 hasConcept C2776403814 @default.
• W2046290421 hasConcept C2778257484 @default.
• W2046290421 hasConcept C2779874844 @default.
• W2046290421 hasConcept C2779951463 @default.
• W2046290421 hasConcept C2781372952 @default.
• W2046290421 hasConcept C2908647359 @default.
• W2046290421 hasConcept C41008148 @default.
• W2046290421 hasConcept C44249647 @default.
• W2046290421 hasConcept C548259974 @default.
• W2046290421 hasConcept C71924100 @default.
• W2046290421 hasConcept C94124525 @default.
• W2046290421 hasConcept C99454951 @default.
• W2046290421 hasConceptScore W2046290421C118487528 @default.
• W2046290421 hasConceptScore W2046290421C118552586 @default.
• W2046290421 hasConceptScore W2046290421C119767625 @default.
• W2046290421 hasConceptScore W2046290421C126322002 @default.
• W2046290421 hasConceptScore W2046290421C142052008 @default.
• W2046290421 hasConceptScore W2046290421C142724271 @default.
• W2046290421 hasConceptScore W2046290421C143095724 @default.
• W2046290421 hasConceptScore W2046290421C151956035 @default.
• W2046290421 hasConceptScore W2046290421C154945302 @default.
• W2046290421 hasConceptScore W2046290421C156957248 @default.
• W2046290421 hasConceptScore W2046290421C159110408 @default.
• W2046290421 hasConceptScore W2046290421C2776058522 @default.
• W2046290421 hasConceptScore W2046290421C2776403814 @default.
• W2046290421 hasConceptScore W2046290421C2778257484 @default.
• W2046290421 hasConceptScore W2046290421C2779874844 @default.
• W2046290421 hasConceptScore W2046290421C2779951463 @default.
• W2046290421 hasConceptScore W2046290421C2781372952 @default.
• W2046290421 hasConceptScore W2046290421C2908647359 @default.
• W2046290421 hasConceptScore W2046290421C41008148 @default.
• W2046290421 hasConceptScore W2046290421C44249647 @default.
• W2046290421 hasConceptScore W2046290421C548259974 @default.

• next